The radiation used in hadrontherapy treatments interacts with the patient body producing secondary particles, either neutral or charged, that can be used for dose and Bragg peak monitoring and to provide a fast feedback on the treatment plans. Recent results obtained from the authors on simplified setups (mono-energetic primary beams interacting with homogeneous tissue-like target) have already indicated the correlation that exists between the flux of these secondaries coming from the target (e.g. protons and photons) and the position of the primary beam Bragg peak. In this paper, the measurements of charged particle fluxes produced by the interaction of a 220 MeV/u carbon ion beam at GSI, Darmstadt, with a polymethyl methacrylate target are reported. The emission region of protons (p), deuterons (d) and tritons (t) has been characterized using a drift chamber while the particle time-of-flight, used to compute the kinetic energy spectra, was measured with a LYSO scintillator. The energy released in the LYSO crystal was used for particle identification purposes. The measurements were repeated with the setup at 60° and 90° with respect to the primary beam direction. The accuracy on the fragments emission profile reconstruction and its relationship with the Bragg peak position have been studied. Based on the acquired experimental evidence, a method to monitor the dose profile and the position of the Bragg peak inside the target is proposed.

The authors presented a simple simulation model for therapeutical (4)He beams which they introduced in TRiP98, and which is validated experimentally by means of physical and biological dosimetries. Thus, it is now possible to perform detailed treatment planning studies with (4)He beams, either exclusively or in combination with other ion modalities.

The purpose of this work was to design and manufacture a 3D range-modulator for scanned particle therapy. The modulator is intended to create a highly conformal dose distribution with only one fixed energy, simultaneously reducing considerably the treatment time. As a proof of concept, a 3D range-modulator was developed for a spherical target volume with a diameter of 5 cm, placed at a depth of 25 cm in a water phantom. It consists of a large number of thin pins with a well-defined shape and different lengths to modulate the necessary shift of the Bragg peak. The 3D range-modulator was manufactured with a rapid prototyping technique. The FLUKA Monte Carlo package was used to simulate the modulating effect of the 3D range-modulator and the resulting dose distribution. For that purpose, a special user routine was implemented to handle its complex geometrical contour. Additionally, FLUKA was extended with the capability of intensity modulated scanning. To validate the simulation results, dose measurements were carried out at the Heidelberg Ion Beam Therapy Center with a 400.41 MeV/u C beam. The high resolution dosimetric measurements show a good agreement between simulated and measured dose distributions. Irradiation of the monoenergetic raster plan took 3 s, which is approximately 20 times shorter than a comparable plan with 16 different energies. The combination of only one energy and a 3D range-modulator leads to a tremendous decrease in irradiation time. 'Interplay effects', typical for moving targets and pencil beam scanning, can be immensely reduced or disappear completely, making the delivery of a homogeneous dose to moving targets more reliable. Combining high dose conformity, very good homogeneity and extremely short irradiation times, the 3D range-modulator is considered to become a clinically applicable method for very fast treatment of lung tumours.

Irradiation of moving targets using a scanned ion beam can cause clinically intolerable under- and overdosages within the target volume due to the interplay effect. Several motion mitigation techniques such as gating, beam tracking and rescanning are currently investigated to overcome this restriction. To enable detailed experimental studies of potential mitigation techniques a complex thorax phantom was developed. The phantom consists of an artificial thorax with ribs to introduce density changes. The contraction of the thorax can be controlled by a stepping motor. A robotic driven detector head positioned inside the thorax mimics e.g. a lung tumour. The detector head comprises 20 ionization chambers and 5 radiographic films for target dose measurements. The phantom's breathing as well as the 6D tumour motion (3D translation, 3D rotation) can be programmed independently and adjusted online. This flexibility allows studying the dosimetric effects of correlation mismatches between internal and external motions, irregular breathing, or baseline drifts to name a few. Commercial motion detection systems, e.g. VisionRT or Anzai belt, can be mounted as they would be mounted in a patient case. They are used to control the 4D treatment delivery and to generate data for 4D dose calculation. To evaluate the phantom's properties, measurements addressing reproducibility, stability, temporal behaviour and performance of dedicated breathing manoeuvres were performed. In addition, initial dosimetric tests for treatment with a scanned carbon beam are reported.

Helium ion beam therapy for the treatment of cancer was one of several developed and studied particle modalities in the 1950’s, leading to clinical trials beginning in 1975 at the Lawrence Berkeley National Laboratory. The trial shutdown was followed by decades of research and clinical silence on the topic while proton and carbon ion therapy made debuts at research facilities and academic hospitals worldwide. The lack of progression in understanding of principle facets of helium ion beam therapy in terms of physics, biological and clinical findings persist today, mainly attributable to its highly limited availability. Despite this major setback, there has been an increasing focus on evaluating and establishing clinical and research programs using helium ion beams, with both therapy and imaging initiatives to supplement the clinical palette of radiotherapy in the treatment of aggressive disease and sensitive clinical cases. Moreover, due its intermediate physical and radio-biological properties between proton and carbon ion beams, helium ions may provide a streamlined economic steppingstone towards an era of widespread use of multi-particle approaches to light and heavy ion therapy. This roadmap presents an overview of the current state-of-the-art and future directions of helium ion therapy: understanding physics and improving modeling, understanding biology and improving modeling, imaging techniques using helium ions and refining and establishing clinical approaches and aims from learned experience with protons. These topics are organized and presented into three main sections, outlining current and future tasks in establishing clinical and research programs using helium ion beams — A. Physics B. Biological and C. Clinical Perspectives.